Apr 26, 2019   SOURCE: PR NewsWire

Global HDAC (histone deacetylase) Inhibitors Market to 2023 Featuring Celgene, Merck & Co, Novartis, Shenzhen Chipscreen Biosciences, & Spectrum Pharmaceuticals

DUBLIN, April 26, 2019 /PRNewswire/ -- The "Global HDAC (histone deacetylase) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The HDAC (histone deacetylase) inhibitors market will register a CAGR of nearly 7% by 2023.

The development of novel drug delivery systems and combination therapies will drive the HDAC inhibitors market growth during the forecast period. Chemotherapeutic drugs are increasingly being administered orally or intravenously for treating different tumors.

However, there are instances that these active pharmaceutical ingredients often do not reach the targeted site in appropriate quantities, eventually, lowering the performance of the drugs. As a result, with the rising shift of research and prescription toward combination therapies using HDAC inhibitors, the market is expected to witness considerable growth during the forthcoming years.

Market Overview

High prevalence of oncology indications

One of the growth drivers of the global HDAC (histone deacetylase) inhibitors market is the high prevalence of oncology indications. The high growth in various types of cancers and neurologic conditions, coupled with high unmet need in the treatment landscape of these diseases will drive the growth of the market.

High costs associated with treatment

One of the challenges in the growth of the global HDAC (histone deacetylase) inhibitors market is the high costs associated with treatment. The high treatment costs act as a barrier for drug adoption, which reduces the patient base and poses a challenge to market growth.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Companies are focusing on research on several other types of cancers using HDAC inhibitors due to their high target affinity and specificity. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

    --  Market ecosystem
    --  Market characteristics
    --  Market segmentation analysis

PART 04: MARKET SIZING

    --  Market definition
    --  Market sizing 2018
    --  Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

    --  Bargaining power of buyers
    --  Bargaining power of suppliers
    --  Threat of new entrants
    --  Threat of substitutes
    --  Threat of rivalry
    --  Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY ROA

    --  Market segmentation by RoA
    --  Comparison by RoA
    --  Oral HDAC inhibitors - Market size and forecast 2018-2023
    --  Parenteral HDAC inhibitors - Market size and forecast 2018-2023
    --  Market opportunity by RoA

PART 08: GEOGRAPHIC LANDSCAPE

    --  Geographic segmentation
    --  Geographic comparison
    --  North America - Market size and forecast 2018-2023
    --  Europe - Market size and forecast 2018-2023
    --  Asia - Market size and forecast 2018-2023
    --  ROW - Market size and forecast 2018-2023
    --  Key leading countries
    --  Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

    --  Market drivers
    --  Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

    --  Overview
    --  Landscape disruption
    --  Competitive scenario

PART 13: VENDOR ANALYSIS

    --  Vendors covered
    --  Vendor classification
    --  Market positioning of vendors

    --  Celgene Corp
    --  Merck & Co., Inc.
    --  Novartis AG
    --  Shenzhen Chipscreen Biosciences Co., Ltd.
    --  Spectrum Pharmaceuticals, Inc.

PART 14: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/tum4d0

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-hdac-histone-deacetylase-inhibitors-market-to-2023-featuring-celgene-merck--co-novartis-shenzhen-chipscreen-biosciences--spectrum-pharmaceuticals-300839172.html

SOURCE Research and Markets